GlassScriptPhysician profile
Syed S Jaffri
NPI 1053369199
$9,893.84
in general payments reported to CMS, 2019-2025
30 companies · $2,033 in 2025
The $2,033 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,655 · 2020: $1,362 · 2021: $1,602 · 2022: $1,143 · 2023: $1,037 · 2024: $1,062 · 2025: $2,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,132.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $1,211.85 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,163.65 | 2020-2025 | Caplyta |
| Abbvie INC. | $983.04 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $941.87 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $799.82 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $721.16 | 2019-2025 | Spravato |
| Alkermes, INC. | $593.38 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $531.30 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $471.68 | 2019-2022 | |
| Lundbeck LLC | $403.15 | 2019-2025 | Rexulti, Brintellix |
| Takeda Pharmaceuticals U.S.A., INC. | $398.88 | 2019-2024 | Trintellix |
| Allergan, INC. | $357.85 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $269.54 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $217.44 | 2022-2025 | Auvelity |
| Janssen Scientific Affairs, LLC | $131.01 | 2025 | Invega Sustenna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $98.21 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Bausch Health US, LLC | $94.04 | 2020-2021 | |
| Eisai INC. | $87.06 | 2020-2021 | |
| Almatica Pharma LLC | $79.50 | 2021-2023 | Loreev Xr, Gralise |
| Idorsia Pharmaceuticals US INC | $63.57 | 2022-2023 | Quviviq |
| Neos Therapeutics, LP | $62.55 | 2019-2025 | Exxua |
| Indivior INC. | $47.67 | 2019-2024 | Sublocade |
| Noven Therapeutics, LLC | $37.48 | 2024 | Xelstrym, Secuado |
| Acadia Pharmaceuticals INC | $28.02 | 2019 | |
| Avanir Pharmaceuticals, INC. | $21.65 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.92 | 2019 | |
| Collegium Pharmaceutical, INC. | $16.32 | 2025 | Jornay Pm |
| Alfasigma USA, INC. | $15.71 | 2020 | |
| Neuronetics, INC. | $14.90 | 2023 | Neurostar Tms Therapy System |
| Adlon Therapeutics L.P. | $14.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Jaffri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.